Hematologic malignancies are a heterogeneous group of conditions with an unclear etiology. We hypothesized that diabetes mellitus type 2 (DM2) is associated with increased risk of developing leukemia, lymphoma and myeloma. A literature search identified 26 studies (13 case-control and 13 cohort studies) evaluating such association. Outcome was calculated as odds ratio (OR) using a random effects model.
Introduction
Hematologic malignancies are a heterogeneous group of diseases characterized by the malignant uncontrolled growth of hematopoietic cells. According to Surveillance, Epidemiology and End Results (SEER) data, approximately 75,000, 45,000 and 20,500 individuals would have been diagnosed with lymphoma, leukemia and myeloma, respectively, during 2011 in the United States (US) alone 1 . The development of hematologic malignancies has been associated to different causes, such as infectious processes (e.g. HTLV-1 and adult T-cell leukemia/lymphoma), autoimmune disorders (e.g. rheumatoid arthritis, Sjogren's syndrome and systemic lupus erythematosus) or a positive family history. However, despite recent advances in the understanding of their pathophysiology, the etiology of these conditions remains largely unexplained.
On the other hand, diabetes affects approximately 25.8 million people in the US 2 . It is estimated that diabetes mellitus type 2 (DM2) accounts for 90-95% of all diabetes cases. DM2 has been studied as a potential risk factor for the development of hematologic malignancies; however, studies evaluating such an epidemiological association have rendered conflicting results. In a previous meta-analysis evaluating the association between diabetes and incidence of lymphoma 3 , we found a stronger association for DM2 and non-Hodgkin lymphoma (NHL). However, NHL subtype analyses were not performed given the paucity of the data available at the time.
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The primary objective of our study was to evaluate the potential association between DM2 and the incidence of lymphoma, leukemia and myeloma. Secondary objectives were to evaluate the association between DM2 and specific subtypes of lymphoma and leukemia.
Methods

Literature Search
Two authors independently performed a literature search using Pubmed/MEDLINE and the Cochrane Database of Systematic Reviews through December 31, 2011. The key terms used in the search were: "diabetes AND (leukemia or lymphoma or myeloma)".
The titles and abstracts were reviewed and full-text articles were selected based on our inclusion criteria. The reference list of each selected study was reviewed looking for additional studies.
Inclusion and Exclusion Criteria
An article was considered relevant if it contained original data from epidemiologic observational studies, either prospective cohort or case-control, reporting on association between DM2 and the incidence of lymphoma, leukemia and myeloma in adults, regardless of the language in which it was published with a minimum follow-up of 3 years and reported or provided sufficient information to allow the calculation of odds For personal use only. on November 16, 2017. by guest www.bloodjournal.org From 5 ratio (OR). Cross-sectional studies were excluded. Any discrepancies on inclusion or exclusion of a study were resolved through consensus in all cases. If there were multiple publications from the same study, only the most recent was selected, using the older publications only to clarify methodology or characteristics of the population.
Data Extraction
The data extraction was performed independently by two authors, and included author,
year of publication, country of origin, sample size, inclusion and exclusion criteria, and methods of ascertainment of DM2, leukemia, lymphoma and myeloma. For cohort studies, we extracted the source of the cohort, years of follow-up, the source of the expected incidence, the outcome measured, and the variables used for adjustment. Any discrepancies were addressed by a joint reevaluation of the original article with another author. For missing information, attempts were made to contact the authors of the original studies. The characteristics and quality of the studies included in this metaanalysis and their outcomes will be presented in accordance to the checklist proposed by the Meta-analysis Of Observational Studies group 4 .
Quality Assessment
The quality of the selected studies was assessed independently by two authors using the Newcastle-Ottawa Scale (NOS) 5 . The NOS uses two different tools for case-control and cohort studies and consists of three parameters of quality: selection, comparability, 6 and exposure/outcome assessment. The NOS assigns a maximum of four points for selection, two points for comparability and three points for exposure or outcome. We assigned NOS scores of 1-3, 4-6 and 7-9 for low, intermediate and high-quality studies, respectively. Any discrepancies were addressed by a joint reevaluation of the original article.
Data synthesis and analysis
Because the risk of leukemia, lymphoma or myeloma in the general population is low, the relative risk obtained from prospective cohort studies numerically approximates the OR 6 ; therefore, permitting the combination of case-control and cohort studies. Hence, the primary outcome measured was odds ratio (OR) with 95% confidence interval (95% CI) of developing leukemia, lymphoma or myeloma in patients with a diagnosis of DM2.
To measure the outcome, the DerSimonian-Laird or random-effects model (REM) was used 7 . The REM accounts for heterogeneity between and within studies. We assessed for heterogeneity using the I 2 index 8 ; I 2 values of 25%, 50% and 75% were considered a reflection of mild, moderate and severe heterogeneity, respectively. Publication bias was addressed by the trim-and-fill method 9 , which estimated and adjusted for the potential effect that non-published (imputed) studies might have had on the measured outcome. Meta-analyses were performed for lymphoma, myeloma and leukemia separately. Lymphoma was separated in NHL and Hodgkin lymphoma (HL). NHL subtypes were diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and
peripheral T-cell lymphoma (PTCL). Leukemia subtypes were lymphoid and myeloid.
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Subset analyses were performed by study design, sex and geographical region. All calculations and graphs were obtained with Comprehensive Meta-Analysis version 2.2.050 (Biostat Inc, New Jersey, USA). In the forest plots, OR values >1 represent a direct association and <1 an inverse association. The size of the squares correlates with the weight of the respective study.
Results
Search results
From 2,029 initial returns, 1,992 articles were rejected because they were reviews, case reports or did not pertain to our study. By reviewing the reference lists of the remaining 37 articles, 7 studies were added. From these 44 studies, 18 were rejected because they did not focus on incidence of leukemia, lymphoma or myeloma, did not focus on DM2 or were cross-sectional. Finally, 26 studies (13 prospective cohort [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and 13 case-control studies [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ) were included in our analysis.
Characteristics of the studies
The main characteristics of the studies included in this analysis are shown on Supplemental Data. Cohort studies were published between 1982 and 2010. Eight studies originated from Europe, three from America and two from Asia, accounting for approximately 8,000 cases identified in a cohort of over 7 million individuals. According For personal use only. on November 16, 2017. by guest www.bloodjournal.org From to the NOS, 11 studies (85%) were of high quality and 2 (15%) of acceptable quality.
The most common selection bias was that there was not a non-exposed cohort but rather expected number of cases in 5 studies (38%). The most common outcome bias was the lack of report of completeness of follow-up in 9 studies (69%). Case-control studies were published between 1987 and 2010. Six studies originated from Europe, five from America and two from Asia, including A total of 9,282 cases and 155,109 controls. According to the NOS, 7 studies (54%) were of high quality and 6 (46%) of acceptable quality. Twelve studies (92%) had population-based controls. The most common selection bias was that cases were not confirmed independently in 10 studies (77%), and the most common exposure bias was that DM2 was self-reported in 9 studies (69%).
Outcome results
Complete subset analyses are shown in Table 1 . Publication bias analyses did not affect our results.
Lymphoma. Twenty-one studies reported on the association between DM2 and incidence of lymphoma [10] [11] [12] [13] [14] [16] [17] [18] [19] [20] [21] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . The OR of NHL was elevated at 1.22 (95% CI 1.07-1.39; p<0.01; Figure 1 ) but there was no association with HL (OR 1.02, 95% CI 0.86-1.19; p=0.86). The association with NHL remained significant when evaluating retrospective and prospective studies separately. There was a statistical trend when evaluating the odds of NHL in men as well as women. According to the region of report, Leukemia. Eleven studies reported data on the association between DM2 and leukemia 10, 13, 15, 16, 19, 20, 22, 24, 27, 33, 34 . Six studies reported data on leukemia in general 10, 13, 15, 19, 20, 22 , 3 studies on chronic lymphocytic leukemia (CLL) 16, 24, 27 , and 2 studies as either myeloid or lymphoid leukemia 33, 34 . The OR of leukemia in patients with DM2 was 1.22 (95% CI 1.03-1.44; p=0.02; Figure 2 ). The odds of leukemia were elevated in prospective cohort studies but not in case-control studies. The odds of leukemia were also elevated in men but not in women. The odds of leukemia were elevated in Asian and American but not in European studies. No clear association was found when evaluating lymphoid or myeloid leukemia separately.
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Myeloma. Ten studies reported data on the association between DM2 and myeloma 10, 13, 16, 17, 19, 22, 23, 27, 33, 34 . The OR of myeloma in patients with DM2 was 1.22 (95% CI 0.98-1.53; p=0.08; Figure 3 ). There were no significant associations when evaluating the studies by design, sex or geographical region, with exception of a trend in Asian studies.
Discussion
The results of our study showed: 1) patients with DM2 have mild-to-moderate increased odds of developing NHL but not HL, 2) when evaluating NHL subtypes, the odds of PTCL were increased in patients with DM2, but not DLBCL and FL, 3) although the odds of leukemia in general were increased, we did not identify an association with myeloid or lymphoid leukemia, 4) there was a trend towards increased odds of myeloma, and 5) the increased odds of hematologic malignancies in patients with DM2 seemed to be distinct depending on the geographical area of report.
The association between DM2 and lymphoma in general has not been completely elucidated. Based on our results, the increased odds of lymphomas in general in patients with DM2 are largely dependent on increased odds of NHL. In a previous study, we identified a significant association between diabetes in general and NHL 3 , however, there was not a statistically significant association between DM2 and NHL (RR 1.3, 95% CI 0.9-1.9). The present study includes larger and more recent prospective datasets. In fact, the number of prospective studies has increased from five to thirteen in the last 3 years, allowing the identification of an association likely derived from a larger number of subjects studied. We believe the present results help establish an epidemiological relationship, which would need further prospective evaluation.
To our knowledge, this is the first meta-analysis evaluating the relationship between DM2 and incidence of leukemia. Interestingly, despite identifying statistically significant odds of leukemia in general in patients with DM2, our study failed to identify a subtype of leukemia driving this association. The most likely explanation for this is the lack of power, as fewer studies evaluating leukemia were included in our analysis. There are, however, other potential explanations for our findings. Many studies reported the odds of lymphoid leukemia without specifying the subtype. For example, 3 studies reported outcomes for CLL, and 2 studies for lymphoid leukemia in general. Hence, one could assume our results would mostly reflect the odds of CLL, the most common lymphoid leukemia in adults. However, some cases of acute lymphoblastic leukemia and other subtypes of lymphocytic leukemia could have been included. A similar situation could have occurred for myeloid leukemia. One could assume the most common myeloid leukemia in adults would be acute myelogenous leukemia; however, potentially some cases of chronic myelogenous leukemia were also included. Therefore, the association between DM2 and leukemia needs further study.
The association between DM2 and myeloma has not been previously evaluated using meta-analytical methodology. Our study shows a statistical trend towards significantly increased odds of myeloma in patients with DM2. In general, DM2 seems to be For personal use only. on November 16, 2017. by guest www.bloodjournal.org From associated with increased odds of lymphoproliferative disorders and it would not be surprising to establish, with a larger number of patients, an association between DM2 and myeloma as well. However, based on the current evidence, this remains speculative.
Our study also shows that the odds of leukemia, lymphoma and myeloma seem to differ depending on the geographical region of report. The odds of NHL were higher in Asia and Europe while the odds of leukemia were higher in America and Asia. Although this is a novel finding, it is likely other confounders such as genetic predisposition, lifestyle factors and viral exposures could have partially affected our results making our associations weaker. Additionally, these results were derived from small sample analyses and should be taken with caution.
There are several potential biological explanations for a relationship between DM2 and malignancies. In this regard, the American Diabetes Association and the American Cancer Society have published a joint consensus report on diabetes and cancer 36 .
Among the multiple points addressed in the report, possible biologic links were discussed. Hyperinsulinemia, hyperglycemia, inflammatory cytokines oversecretion, insulin-like growth factor (IGF) overproduction and up-regulation of IGF-1 receptor are phenomena seen in patients with DM2, which would favor not only malignant transformation of cells but also progression of tumors. However, the epidemiological association between DM2 and cancer seen in multiple studies does not formally establish DM2 as a cause of cancer. To further complicate this issue, DM2 and cancer For personal use only. on November 16, 2017. by guest www.bloodjournal.org From 13 share common risk factors, such as age, sex, overweight and obesity, waist-to-hip ratio, physical activity, dietary habits, smoking and alcohol intake, making difficult to discern the oncogenic effect of each specific risk factor. As an example, a recent meta-analysis has shown an increased risk of several cancers associated with obesity 37 . Future prospective studies should focus on evaluating the impact that these risk factors could have on the incidence of hematologic malignancies and specific subtypes by means of carefully designed multivariate analyses. Similarly, other factors, such as DM2 duration and severity as well as the use of insulin or other antidiabetic therapies, should also be evaluated.
DM2 is a condition associated with immunosuppression, chronic inflammation and B
and T-cell dysfunction 38, 39 , which have been associated with the development of lymphoproliferative disorders 40, 41 . Specifically for the association found in our study between DM2 and PTCL, there is mounting evidence of an intrinsic T-cell dysfunction in patients with DM2 demonstrated by weaker T-cell-mediated responses to antigen exposure 42 , and a skewed balance favoring the activation of pro-inflammatory T-cell subsets 43, 44 . The fact that certain autoimmune conditions such as psoriasis or celiac disease increase the risk of PTCL further support these hypotheses 42, 43 .
Our meta-analysis carries several weaknesses based on the quality of the included studies. First, there was a high degree of heterogeneity between studies secondary to the diversity of patients, histological subtypes and study designs. The effect of heterogeneity was addressed by using the REM. Furthermore, when evaluating specific For personal use only. on November 16, 2017. by guest www.bloodjournal.org From subtypes of lymphoma and leukemia, the heterogeneity became less evident. Second, the diagnosis of DM2 was self-reported in a substantial number of the studies, which could have introduced ascertainment bias. However, diabetes self-reporting has shown to be reliable in large epidemiological prospective studies such as the Women's Heath Initiative 45 . And third, there are several potential confounders, which effects were partially addressed by the present study; 22 studies (85%) either adjusted or matched for age, 13 (50%) for sex, 12 (46%) for geographical region or race, and 4 (15%) for body mass index. Hence, the effects of age, sex and geographical region were likely accounted for in our study, but not other important factors such as obesity, diet, physical activity or antidiabetic therapy. It is likely there is interaction between these factors, cancer incidence and DM2, which could weaken our results; however, these should be further investigated.
Nevertheless, our study has several strengths. First, the number of cases included was large rendering our study powerful enough to evaluate the epidemiological association between DM2 and leukemia, lymphoma and myeloma. Second, the included studies originated from different countries and included a variety of ethnic backgrounds, allowing the generalization of our results. Third, based on the NOS, all the studies included in this meta-analysis were of acceptable or high quality. Specifically in casecontrol studies, in which selection bias can be easily introduced, the large majority used age-and sex-matched, population-based controls originating from the same geographical regions as the cases, minimizing potential differences in medical care or ascertainment. Lastly, publication bias did not affect our results. 
Conclusions
The present meta-analysis shows that patients with a diagnosis of DM2 have increased odds of developing NHL, leukemia and myeloma. Regarding lymphoma subtypes, DM2 was associated with increased odds of PTCL in a small subset analysis. Additional studies are needed to elucidate the potential relationship between DM2 and hematologic malignancies. 
